Pipeline

Anti-Prionic MoA

Priavoid’s pharmaceutical development pipeline with anti-prionic drug candidates is composed of 5 development programs for 5 CNS diseases:

 

  • Alzheimer’s disease
  • Tauopathies
  • Parkinson’s disease
  • Amyotrophic Lateral Sclerosis
  • Huntington’s disease
all-D-Peptide Pipeline

Non-Anti-Prionic MoA

Priavoid’s pharmaceutical development pipeline with non-anti-prionic drug candidates is composed of 2 development programs for 2 CNS diseases:

 

  • Amyotrophic Lateral Sclerosis
  • Neuropathic Pain
all-D-Peptide Pipeline

PRI-002

PRI-002

is the most advanced drug in our pipeline for the causal treatment of Alzheimer’s disease (AD).

 

Thus, PRI-002 has three unique selling propositions (USPs):

 

New mechanism of action
Specific elimination of toxic Aβ oligomers

New drug substance class
Synthetic all-D-peptide

Oral drug administration
Protease resistant

Intervention Strategy

Intervention Strategy

Priavoid developed a completely new therapeutic strategy for the causal treatment of Alzheimer’s disease.  The orally available D-peptide PRI-002  permeates the blood-brain barrier effectively, does not interfere with formation or clearance of non-toxic Aß monomers, but specifically eliminates cytotoxic  Aß-oligomers.

 

Partnering

Partnering is a key component of Priavoids strategy

Learn more